BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19198893)

  • 1. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
    Ribi K; Koeberle D; Schuller JC; Honegger H; Roth A; Hess V; Moosmann P; von Moos R; Borner M; Lombriser N; Pestalozzi B; Ruhstaller T
    Support Care Cancer; 2009 Aug; 17(8):1109-16. PubMed ID: 19198893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer.
    Bonnetain F; Bouché O; Michel P; Mariette C; Conroy T; Pezet D; Roullet B; Seitz JF; Paillot B; Arveux P; Milan C; Bedenne L
    Ann Oncol; 2006 May; 17(5):827-34. PubMed ID: 16524973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer.
    Steffen T; Dietrich D; Schnider A; Kettelhack C; Huber O; Marti WR; Furrer M; Gloor B; Schiesser M; Thierstein S; Brauchli P; Ruhstaller T;
    Ann Surg; 2019 Jan; 269(1):83-87. PubMed ID: 28742685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporary placement of self-expanding oesophageal stents as bridging for neo-adjuvant therapy.
    Langer FB; Schoppmann SF; Prager G; Tomaselli F; Pluschnig U; Hejna M; Schmid R; Zacherl J
    Ann Surg Oncol; 2010 Feb; 17(2):470-5. PubMed ID: 19859771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
    Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
    Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction.
    Sunde B; Ericson J; Kumagai K; Lundell L; Tsai JA; Lindblad M; Rouvelas I; Friesland S; Wang N; Nilsson M
    Dis Esophagus; 2016 Jul; 29(5):442-7. PubMed ID: 25809837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
    Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
    Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
    Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
    Pellen MG; Sabri S; Razack A; Gilani SQ; Jain PK
    Dis Esophagus; 2012 Jan; 25(1):48-53. PubMed ID: 21595778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
    Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
    Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.
    Coker AM; Barajas-Gamboa JS; Cheverie J; Jacobsen GR; Sandler BJ; Talamini MA; Bouvet M; Horgan S
    J Laparoendosc Adv Surg Tech A; 2014 Feb; 24(2):89-94. PubMed ID: 24401141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.
    McNamara MJ; Adelstein DJ; Allende DS; Bodmann JW; Ives DI; Murthy SC; Raymond D; Raja S; Rodriguez CP; Sohal D; Stephans KL; Videtic GMM; Rybicki LA
    J Gastrointest Cancer; 2017 Jun; 48(2):181-189. PubMed ID: 27734205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.